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Of the various derivatives of caffeic acid, caffeic acid phenethyl ester (CAPE) is a hydro-
phobic, bioactive polyphenolic ester obtained from propolis extract. The objective in
writing this review article was to summarize all published studies on therapeutics of CAPE
in inflammation and cancer to extract direction for future research. The possible molecular
targets for the action of CAPE, include various transcription factors such as nuclear factor-
kB, tissue necrosis factor-a, interleukin-6, cyclooxygenase-2, Nrf2, inducible nitric oxide
synthase, nuclear factor of activated T cells, hypoxia-inducible factor-1a, and signal
transducers and activators of transcription. Based on the valuable data on its therapeutics
in inflammation and cancer, clinical studies of CAPE should also be conducted to explore
its toxicities, if any.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.  Open access under CC BY-NC-ND license.1. Introduction
Due to the lethal side effects of synthetic chemical-based
drugs, enthusiastic efforts are currently being applied to
explore natural therapeutic agents with minimum toxicity. In
this context, plant or herbal origin compounds are being
studied to investigate the bioactivities of their natural activemacy, COMSATS Institut
(G. Murtaza).
ministration, Taiwan. Publcompounds. Polyphenols represent one of the most inten-
sively studied groups of natural compounds.
Caffeic acid has been proposed to act as a multipurpose
active polyphenol and its derivatives have also been subjected
to considerable study. One of the derivatives of caffeic acid is
caffeic acid phenethyl ester (CAPE), which possesses prom-
ising therapeutic potential against various pathologies such as
inflammation, cancer, infection, and neurodegeneratione of Information Technology, Abbottabad 22060, Pakistan.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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ester occurs in numerous plants [6e9] and propolis [10] and
can also be prepared by reacting caffeic acid with phenethyl
alcohols [1e3]. Themolecular formula of CAPE is C17H16O4 and
is chemically recognized as 2-phenylethyl (2E)-3-(3,4-
dihydroxyphenyl)acrylate (commonly termed as phenylethyl
caffeate or phenethyl caffeate) [4].
To achieve biological effects, CAPE should be adminis-
tered at a therapeutic concentration so that prolonged
maintenance of blood CAPE-concentration at a particular
level could be achieved. Thus pharmacokinetic and
bioavailability study of CAPE is crucial for determining its
route of administration. Fig. 1 depicts the chemical struc-
ture of CAPE consisting of a catechol ring and two hydroxyl
groups; the former is considered to be responsible for its
therapeutic features [5]. It has been proposed that meta-
bolism of CAPE is a saturable process because an increase in
the area under the plasma concentrationetime curve for
CAPE was observed in a proportion higher than the increase
in its dose. Moreover, volume of distribution and total body
clearance values for CAPE were found to be in the ranges of
1555e5209 mL/kg and 42e172 mL/minute/kg, respectively,
proposing that these values are in an inverse relationship
with the dose of CAPE. Additionally, no relationship was
observed between the values of elimination half-life
(21.24e26.71 minutes) of CAPE and its dose. Pharmacoki-
netic study of CAPE showed its high values of volume of
distribution and short elimination half-life, revealing its
extensive distribution and swift elimination from the body
after intravenous administration [11]. Another pharmaco-
kinetic study of CAPE showed comparable results [12].
Furthermore, pharmacokinetic analysis of CAPE and its
metabolites should also be carried out after its oral
administration. Another study has revealed that CAPE can
efficiently cross the bloodebrain barrier in rats [13]. Besides,
although CAPE is stable for 6 hours in rat plasma, after
which it hydrolyzes to caffeic acid, CAPE hydrolysis does
not occur in human plasma showing its stability, possibly
owing to the absence of carboxylesterase in this biofluid
[14,15].
After an extensive search, no data were found about
toxicity study of CAPE. Rather, slight toxicity of propolis was
seen in a range of 2000e7300 g of propolis/kg inmice that is an
origin of CAPE [16,17]. At a dose of approximately 80 mM, CAPE
generally inhibits the activated nuclear factor-kB (NF-kB) and
other transcription factors via suppressing their binding with
DNA [15].
The objective in writing this review article was to sum-
marize various published studies on the therapeutics of CAPE
in inflammation and cancer, especially focusing on their
molecular targets that are responsible for therapeutic effect of
CAPE.Fig. 1 e Chemical structureof caffeic acidphenethyl ester [9].2. Literature search methodology
An extensive literature search in English was conducted,
using various electronic databases including Medline
(1966e2014) and EMBASE (1980e2014). An initial search was
made using terms caffeic acid phenethyl ester and activity jointly.
Then, other terms such as inflammation, cancer, and molecular
targets were combined with caffeic acid phenethyl ester and ac-
tivity for an advanced search. The literature investigation was
done by assessing the bibliography of the selected publica-
tions showing original research to make a quality review
article.3. Results and discussion
There are many studies in the literature that elaborate the
anti-inflammatory activity of CAPE [18,19]. Moreover, CAPE-
induced inhibition of normal cell transformation to the
neoplastic cell has also been reported [20,21]. Table 1
[20,22e32] elaborates the dose (mM) or concentration causing
50% growth inhibition (mM) of CAPE effective in different
cancer cell-lines. In addition, CAPE selectively destroys the
cancerous cells leaving noncancer cells unaffected as
observed in human immortal lung fibroblast WI-38 cells [29].
These studies hypothesize that CAPE inhibits the release of
arachidonic acid from the cell membrane, and moreover,
suppresses the gene responsible for cyclooxygenase-2 (COX-2)
expression [33e36]. Moreover, CAPE suppresses NF-kB activity
by limiting the formation of NF-kB DNA and nuclear factor of
activated T cells (NFAT)-DNA complexes and thus retarding
NF-kB-dependent transcription in Jurkat cells [37e42]. In 2005,
Abdel-Latif et al presented anticancer and anti-inflammatory
activities of CAPE in a gastric epithelial cell line, claiming that
CAPE inhibits the production of tissue necrosis factor-a (TNF-
a) and interleukin (IL)-8; it eventually retards the expression of
NF-kB, AP-1, and COX-2 [43]. It is noteworthy to mention here
that CAPE does not influence other tissues of body, and thus
the usage of this natural anticancer agent is free of side effects
with effective chemopreventive feature [44e47]. This outcome
elaborates the nutritional importance of CAPE, particularly for
patients whose tumors express gradually elevated levels of
above given activated transcription factors.
Lipopolysaccharide-mediated inflammation in human
neutrophils has also been combated using CAPE which sup-
presses the synthesis of TNF-a and IL-6 [48]. The same authors
also found that CAPE attenuates the phosphorylation of
extracellular signal-regulated kinase 1/2 and c-JunN-terminal
kinase [48]. Raso et al [49] found that CAPE has potential for
reducing inflammation through inhibiting IL-2 gene in acti-
vated T-cells that are normally the source of inflammation
[34].
Biological studies have also revealed the activity of CAPE
against angiogenesis, tumor invasion, metastasis, prolifera-
tion, and apoptosis in different cancers such as human
pancreatic and colon cancer [23,35,44,50e55]. The improve-
ment in the viability of colon adenocarcinoma cells (CT26) has
been noted in a dose-dependent manner when these cells are
treated with CAPE [30]. This cytotoxic effect of CAPE has been
Table 1 e The dose or concentration causing 50% growth inhibition (IC50) of CAPE effective in different cancer cell-lines.
No. Types of cancer and their cell lines Dose (mM) IC50 (mM) Refs
1 U973 myeloid leukemia cells 0.4e53 d [22]
2 GNM neck metastasis of Gingiva carcinoma 25e200 d [23]
3 TSCC tongue squamous carcinoma cells 25e200 d [23]
4 Daoy medulloblastoma cells 1e100 d Lee et al 2005
5 SW480 colon cancer cells 9e18 d Wang et al 2005
6 HCT116 colon cancer cells 9e182 d [24]
7 PC-3 prostate cancer cells 88 d [25]
8 HL-60 leukemia cells 21 d [26], Chen et al 2001b
9 MCF-7 breast cancer cells 10e100 d [27]
10 Meng 1 oral epidermal carcinoma cells 50e200 d [20]
11 H1299 lung cancer cells d 21.2 Lin et al 2011
12 Nalm6 lymphoma cells d 3.1 [28]
13 Farage lymphoma cells d 2.0 [28]
14 Pfeiffer lymphoma cells d 1.2 [28]
15 Ramos lymphoma cells d 4.0 [28]
16 HDMAR lymphoma cells d 2.1 [28]
17 HT-1080 fibrosarcoma cells d 9.5 [29]
18 HeLa cervical cancer cells d 2.4 [29]
19 CT26 colon cancer cells d 35.0 [30]
20 A549 lung cancer cells d 20.9 [29,31]
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loproteinase and synthesis of vascular endothelial growth
factor under the effect of CAPE. In this way, this chemical
activity obstructs the angiogenesis and metastasis [56e62].
CAPE can suppress apoptosis via inhibiting the activated
NF-kB [26], Bak [63], Bcl-2-associated X protein (Bax)
[31,63e65], p53 [25,27,63], extracellular signal-regulated ki-
nase [63], c-Jun and p21ap [27], c-JunN-terminal kinase and
Fas ligand [65], p38 mitogen-activated protein kinase (p38
MAPK) [25,63], and caspase activity [27,31,63,64]. Moreover,
upregulation of Bel-2 [29,66], the cellular inhibitor of apoptosis
proteins 1 and 2, and X-linked inhibitor of apoptosis protein
[26,31], release of cytochrome C [63,64], loss of mitochondrial
transmembrane potential [27], and decrease inMcl-1 [21,27] by
CAPE are also responsible for its antiapoptotic effect.
In many cancer cells, CAPE-mediated-cell cycle arrest has
been reported through the suppression of various factors
including cyclin B1 [28,29]. CAPE-induced necrosis has also
been described [22]. In addition, suppression of AktFig. 2 e Various modes of anticancer activitiephosphorylation is also induced by CAPE, resulting in the in-
hibition of cancer cell invasiveness [24].
The literature also contains many animal studies that
reveal the inhibitory role of CAPE on tumor growth and
metastasis. For example, at a dietary level of 0.15% CAPE,
C57BL/6J-Min/þmice having a germ-linemutation exhibit 63%
suppression in tumor growth through increased apoptosis
and cell proliferation [67]. At a dose of 50 mg/kg, CAPE-treated
rats showed the emergence of colonerectal carcinoma pro-
voked by azoxymethane [44]. In addition, mice with C6 glioma
xenografts have exhibited dose-dependent inhibition in
tumormetastasis at 1e10mg intraperitoneal dose of CAPE/kg/
day [21]. As far as mechanisms of anticancer activity of CAPE
are concerned, CAPE is capable of affecting various processes
[32,42,46,60,68e73] as summarized in Fig. 2.
Through numerous experimental studies, the therapeutic
potentials of CAPE against various cancers have been
explored. The findings of those studies are summarized below
and the possible target sites of CAPE action are also described.s of caffeic acid phenethyl ester (CAPE).
Fig. 3 e A summary of linkage between inflammation and cancer development. Tissue necrosis factor-a (TNF-a), interleukin
(IL)-1, hypoxia-inducible factor-1a (HIF-1a), vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs),
modified citrus pectins (MCPs), endothelial growth factor (EGF), nuclear factor-kB (NF-kB), nuclear factor of activated T cells
(NFAT), signal transducer and activator of transcription 3 (STAT3), vascular cell adhesion molecules (VCAMs), intercellular
adhesion molecules (ICAMs), cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), nitric oxide (NO).
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 3 ( 2 0 1 5 ) 1 1e1 814In response to a stimulus such as tissue damage, inflam-
mation develops. It is a physiologic phenomenon that may
contribute to cancer development through various in-
termediates (Fig. 3) [74]. Key modulators, which drive inflam-
mation to cancer, include various transcription factors such
as NF-kB, TNF-a, IL-6, COX-2, Nrf2, inducible nitric oxide
synthase (iNOS), NFAT, hypoxia-inducible factor-1a, and
signal transducers and activators of transcription [74].
The cytoplasm of all nondiseased B cells contains inactive
NF-kB factor [75]. NF-kB is a collective term referring to
proinflammatory heterotrimer transcription factors, a family
of five proteins having Rel-domain. These proteins, including
NF-kB1 (or p50), NF-kB2 (or p52), Rel A (or p65), Rel B, and c-Rel,
remain inactive under the influence of IkBa, IkBb, IkBg, IkBaε,Fig. 4 e An illustrative summary of the nuclear factor
(NF)-kB activation route.bcl-3, p105, and p100 proteins that have the anchoring domain
[76].
In tumor cells, as well as proliferating thymocytes, mono-
cytes, astrocytes, T cells, and B cells, NF-kB is reported to be
activated after phosphorylation and removal of IkBa by IkBa
kinase (IKK; Fig. 4). The IKK family consists of three enzymes
(IKKa, IKKb, and IKKg), of which, IKKb is proposed to be
involved in NF-kB activation by cytokines (tissue necrosis
factor, IL-6, growth factors, and differentiation factors) and
many other carcinogens and tumor promoters [76e78].
Shishodia et al [79] demonstrated tissue necrosis factor as the
strongest NF-kB activator, under the influence of which tumor
cells proliferate, invade, metastasize, and suppress apoptosis.
Matrix metalloproteinases, urokinase type of plasminogen
activator, and IL-8 are examples of NF-kB-regulated gene
products that regulate the invasion of tumor cells [79e82].
Metastasis of tumor cells is regulated by NF-kB and is medi-
ated through the expression of different adhesion molecules,
including intercellular adhesion molecule-1, vascular cell
adhesion molecule-1, endothelium leukocyte adhesion
molecule-1, and iNOS [83,84].
Immediately after activation, translocation of NF-kB occurs
from the cytoplasm to the nucleus of the cell followed by the
binding of NF-kB to its particular harmonized site consisting of
10 base pairs, GGGPuNNPyPyCC [85,86]. The active NF-kB, in
normal physiology, controls the expression of many genes
that regulate the immune, growth, and inflammation features
of cell.
By contrast, the excessive and improper activation of NF-
kB can intervene inflammation and tumorigenesis. In addi-
tion, NF-kB acts as a linkage between inflammation and
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[45,87]. Thus, activation of NF-kB by any inflammatory agents
can produce inflammation that is mediated through adhesion
molecules, such as intercellular adhesion molecule-1 [88].
Similarly, suppression of NF-kB by any anti-inflammatory
agents can reduce inflammation and proliferation causing
cell cycle arrest, eventually leading to apoptosis [45]. The
microenvironment of tumors, as well as different inflamma-
tory agents, carcinogens, and tumor promoters may activate
the NF-kB [76]. There are some members of the NF-kB group
that are oncogenic in nature and can intervene their effects by
activating NF-kB [76,89].
Various stimuli, such as lipopolysaccharide, proin-
flammatory cytokines (e.g., IL-1 and tissue necrosis factor),
and growth factors (e.g., epidermal growth factor), have been
found to be involved in expression of COX-2, which acts on
arachidonic acids and produces prostaglandins, the crucial
mediators of inflammation.Moreover, COX-2 is overexpressed
in cancer [74,90,91]. Various antioxidant genes are regulated
by Nrf2's role in inflammation; this effect of Nrf2 can be
attributed to the involvement of prostaglandins and/or NO
leading to the diminished susceptibility to apoptotic factors
including TNF-a. Nrf2 is reported to exhibit protection against
DNA damage and carcinogenesis [92,93]. Likewise, iNOS, an
enzyme that catalyzes the production of NO, is also over-
expressed in inflammation and cancer [29,94,95]. In addition,
NFAT is proposed to play a crucial role in inflammatory re-
sponses through the expression of various proinflammatory
cytokines, including IL-2, IL-3, IL-4, IL-5, IL-13, and TNF-a.
NFAT is involved in COX-2 expression induced by TNF-a
[96,97]. By contrast, inflammation is always accompanied by
hypoxia due to metabolic shifts during inflammation. In
response to hypoxia, hypoxia-inducible factor-1a, a hetero-
dimeric transcription factor, activates various molecules
including erythropoietin, iNOS, vascular endothelial growth
factor, and glucose transporter-1 [98e100]. Signal transducers
and activators of transcription factors are also activated by
various cytokines in inflammation and cancer [29].
4. Conclusion
This literature mining study revealed anti-inflammatory and
anticancer activities of CAPE. The possible molecular targets
for the action of CAPE in inflammation and cancer include
various transcription factors such as NF-kB. Based on the
valuable data about the above presented bioactivities, clinical
studies of CAPE should be conducted to explore its toxicities, if
any.Conflicts of interest
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